Galmed Pharmaceuticals (NASDAQ:GLMD) Issues Earnings Results

Galmed Pharmaceuticals (NASDAQ:GLMD) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD stock opened at $0.57 on Friday. The stock’s fifty day moving average is $0.60 and its two-hundred day moving average is $0.66. The firm has a market capitalization of $3.12 million, a P/E ratio of -0.46 and a beta of 0.75. Galmed Pharmaceuticals has a fifty-two week low of $0.41 and a fifty-two week high of $2.34.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Galmed Pharmaceuticals currently has an average rating of “Sell”.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.